In hopes of alleviating potential drug shortages and other issues wrought by the coronavirus pandemic, the Food and Drug Administration drastically rolled back its oversight of compounding pharmacies — a swift and sweeping relaxing of the rules that were put in place after a fungal meningitis outbreak traced to one such center killed more than 60 and sickened over 700.

Public health experts say there’s merit to relaxing the rules amid the pandemic, but they’re already cautioning that there’s no reason to make the changes permanent. Compounders, meanwhile, are gearing up for a fight to do just that.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • One would have thought that the FDA’s laissez-faire approach toward allowing “emergency use” diagnostic tests for detecting antibodies to COVID 19 would have taught all of us a lesson. Apparently not. But the tests are for in vitro use. Should those same dubious practices apply to in vivo products as well?

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy